Summary
Following mediastinoscopy, a prognostically orientated multimodality approach was chosen in selected small-cell lung cancer (SCLC) patients with hyperfractionated accelerated chemoradiotherapy (Hf-RTx) and definitive surgery (S). Stage IB/IIA patients had four cycles of cisplatin/etoposide (PE) and surgery. Stage IIB/IIIA patients had three cycles PE followed by one cycle concurrent chemoradiation including Hf-RTx and surgery. Most stage IIIB patients were not planned for surgery and had CTx followed by sequential RTx or one cycle concurrent CTx/RTx. Of 46 consecutive patients (stage IB six, IIA two, IIB/IIIA 22, IIIB 16) 43 (94%) showed an objective response. Twenty-three of patients (72%) planned for inclusion of S were completely resected (R0) (IB 6/6, IIA 2/2, IIB/IIIA 13/22, IIIB 2/2). Overall toxicity was acceptable – one patient died of septicaemia, no perioperative deaths occurred. Median follow-up of patients alive (n = 21) is 52 months (30+ – 75+). Median survival and 5-year survival rate of all patients are 36 months and 46%, in R0 patients 68 months and 63% (R0-IIB/IIIA/IIIB: not yet reached and 67%). This multimodality treatment including surgery proved highly effective with 100% local control and remarkable long-term survival after complete resection, even in locally advanced SCLC stages IIB/IIIA patients.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Arriagada, R, Kramar, A, Le Chevalier, T & De Cremoux, H (1992). Competing events determining relapse-free survival in limited small-cell lung carcinoma. J Clin Oncol 10: 447–451.
Arriagada, R, Le Chevalier, T, Borie, F, Rivière, A, Chomy, P, Monnet, I, Tardivon, A, Viader, F, Tarayre, M & Benhamou, S (1995). Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst 87: 183–190.
Arriagada, R, Auperin, A, Pignon, JP, Gregor, A, Stephens, R, Kristjansen, PEG, Johnson, B, Ueoka, H, Wagner, H & Whitacre, M (1998). Prophylactic cranial irradiation overview in patients with small-cell lung cancer in complete remission. Proc Am Soc Clin Oncol 17: 457 (abstr 1758)
Choi, NC, Carey, RW, Daly, W, Mathisen, D, Wain, J, Wright, C, Lynch, T, Grossbard, M & Grillo, H (1997). Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer. J Clin Oncol 15: 712–722.
Davis, S, Crino, L, Tonato, M, Darwish, S, Pelicci, PG & Grignani, F (1993). A prospective analysis of chemotherapy following surgical resection of clinical stage I–II small cell lung cancer. Am J Clin Oncol 16: 93–95.
Eberhardt, W, Wilke, H, Stamatis, G, Stuschke, M, Harstrick, A, Menker, H, Krause, B, Müller, MR, Stahl, M, Flasshove, M, Budach, V, Greschuchna, D, Konietzko, N, Sack, H & Seeber, S (1998). Preoperative chemotherapy followed by concurrent chemoradiation therapy based upon hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. J Clin Oncol 16: 622–634.
Elias, AD, Ayash, L, Frei, III E, Skarin, AT, Hunt, M, Wheeler, C, Schwartz, G, Mazanet, R, Tepler, I, Eder, JP, McCauley, M, Herman, T, Schnipper, L & Antman, KH (1993). Intensive combined modality therapy for limited-stage small-cell lung cancer. J Natl Cancer Inst 85: 559–566.
Elias, AD (1997a). Small cell lung cancer: state-of-the-art therapy in 1996. Chest 112: 251S–258S.
Elias, AD (1997b). Dose-intensive therapy in lung cancer. Cancer Chemother Pharmacol 40: S64–S69.
Fetscher, S, Brugger, W, Engelhardt, R, Kanz, L, Hasse, J, Frommhold, H, Wenger, M, Lange, W & Mertelsmann, R (1997). Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer. Ann Oncol 8: 49–56.
Gray, JR, Sobczak, ML, Hahn, SM, Sullivan, FJ, Johnson, BE & Bridges, JD (1995). Analysis of local control in 150 limited stage small-cell-lung cancer patients treated with combined thoracic irradiation and multiagent chemotherapy. Proc Am Soc Clin Oncol 14: 349 (abstr 1056)
Green, MR, Cox, JD, Ardizzoni, A, Arriagada, R, Bureau, G, Darwish, S, Deneffe, G, Fukuoka, M, Joseph, D & Komaki, R (1994). Endpoints for multimodal clinical trials in stage III non-small cell lung cancer (NSCLC): a consensus report. Lung Cancer 11, Suppl 3: S11–S13.
Gridelli, C, D’Aprile, M, Curcio, C, Brancaccio, L, Palmeri, S, Comella, G, Veltri, E, Ferrante, G, Gentile, M & Rossi, A (1994). Carboplatin plus epirubicin plus VP-16, concurrent ‘split course’ radiotherapy, and adjuvant surgery for limited small-cell lung cancer. Lung Cancer 11: 83–91.
Ihde, DC, Pass, HI & Glatstein, EJ (1997). Small cell lung cancer. In: Cancer: Principles and Practice of Oncology, 5th edn, DeVita VT Jr Hellman, S Rosenberg SA (eds), pp. 911–949.Lippincott: Philadelphia 911–949.
Johnson, DH, Kim, K, Sause, W, Komaki, R, Wagner, H, Aisner, S, Livingston, R, Blum, R & Turrisi, AT (1996). Cisplatin and etoposide plus thoracic radiotherapy administered once or twice daily in limited stage small cell lung cancer: Final report of Intergroup Trial 0096. Proc Am Soc Clin Oncol 15: 374 (abstr 1113)
Kaplan, EL & Meier, P (1958). Nonparametric estimation from incomplete observations. J Am Statist Assoc 53: 457–481.
Lad, T, Piantadosi, S, Thomas, P, Payne, D, Ruckdeschel, J & Giaccone, G (1994). A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small-cell lung cancer to combination chemotherapy. Chest 106: 320S–323S.
McCracken, JD, Janaki, LM, Crowley, JJ, Taylor, SA, Shankir Giri, PG, Weiss, GB, Gordon, W, Baker, LH, Mansouri, A & Kuebler, JP (1990). Concurrent chemotherapy/radiotherapy for limited small-cell lung carcinoma: a Southwest Oncology Group study. J Clin Oncol 8: 892–898.
Macchiarini, P, Mussi, A, Basolo, F, Bruno, J & Angeletti, CA (1989). Optimal treatment for T1-3N0M0 small cell lung cancer: surgery plus adjuvant chemotherapy. Anticancer Res 9: 1623–1625.
Mantel, N (1966). Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163–170.
Meyer, JA, Gullo, JJ, Ikins, PM, Comis, RL, Burke, WA, Di Fino, SM & Parker, FB Jr (1984). Adverse prognostic effect of N2 disease in treated small-cell carcinoma of the lung. J Thorac Cardiovasc Surg 88: 495–501.
Miller, AB, Hoogstraten, B, Staquet, M & Winkler, A (1981). Reporting results of cancer treatment. Cancer 47: 207–214.
Mountain, CF (1997). Revisions in the international system staging lung cancer. Chest 111: 1710–1717.
Müller, LC, Salzer, GM, Huber, H, Prior, C, Ebner, I, Frommhold, H & Präuer, HW (1992). Multimodal therapy of small cell lung cancer in TNM stages I through IIIa. Ann Thorac Surg 54: 493–497.
Parker, SL, Tong, T, Bolden, S & Wingo, PA (1997). Cancer statistics, 1997. CA Cancer J Clin 47: 5–27.
Pignon, JP, Arriagada, R, Ihde, DC, Johnson, DH, Perry, MC, Souhami, RL, Brodin, O, Joss, RA, Kies, MS, Lebeau, B, Onoshi, T, Osterlind, K, Tattersall, MHN & Wagner, H (1992). A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 327: 1618–1624.
Shepherd, FA, Evans, WK, Feld, R, Young, V, Patterson, GA, Ginsberg, R & Johansen, E (1988). Adjuvant chemotherapy following surgical resection for small-cell carcinoma of the lung. J Clin Oncol 6: 832–838.
Shepherd, FA, Ginsberg, RJ, Patterson, GA, Evans, WK & Feld, R (1989). A prospective study of adjuvant surgical resection after chemotherapy for limited small cell lung cancer. A University of Toronto Lung Oncology Group study. J Thorac Cardiovasc Surg 97: 177–186.
Shepherd, FA, Ginsberg, RJ, Haddad, R, Feld, R, Sagman, U, Evans, WK, De Boer, G & Maki, E (1993). Importance of clinical staging in limited small-cell lung cancer: a valuable system to separate prognostic subgroups. J Clin Oncol 11: 1592–1597.
Shepherd, F (1996). Surgical management of small-cell lung cancer. InLung Cancer: Principles and Practice, Pass HI, Mitchell JB, Johnson DH, Turrisi AT Lippincott-Raven: Philadelphia 889–913.
Takada, M, Fukuoka, M, Furuse, K, Ariyoshi, Y, Ikegami, H, Kurita, Y, Nishiwaki, Y, Nishiwaki, H, Watanabe, K, Noda, K & Saijo, N (1996). Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small cell lung cancer: Preliminary results of the Japan Clinical Oncology Group. Proc Am Soc Clin Oncol 15: 372 (abstract 1103)
Turrisi, AT, Glover, DJ, Mason, B & Tester, W (1992). Long term results of platinum etoposide + twice-daily thoracic radiotherapy for limited small-cell lung cancer: results on 32 patients with 48 months minimum F/U. Proc Am Soc Clin Oncol 11: 292 (abstract 975)
Turrisi, AT, Kim, K, Blum, R, Sause, WT, Livingston, RB, Komaki, R, Wagner, H, Aisner, S & Johnson, DH ). Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340: 265–271.
Ulsperger, E, Karrer, K & Denck, H (1991). Multimodality treatment for small cell lung cancer. Preliminary results of a prospective, multicenter trial. The ISC-Lung Cancer Study Group. Eur J Cardiothorac Surg 5: 306–310.
Wilke, H, Achterrath, W, Schmoll, HJ, Gunzer, U, Preusser, P & Lenaz, L (1988). Etoposide and split-dose cisplatin in small cell lung cancer. Am J Clin Oncol 11: 572–578.
Zatopek, NK, Holoye, PY, Ellerbroek, NA, Hong, WK, Roth, JA, Ryan, MB, Komaki, R, Pang, AC & Glisson, BS (1991). Resectability of small cell lung cancer following induction chemotherapy in patients with limited disease (stage II–IIIb). Am J Clin Oncol 14: 427–432.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Eberhardt, W., Stamatis, G., Stuschke, M. et al. Prognostically orientated multimodality treatment including surgery for selected patients of small-cell lung cancer patients stages IB to IIIB: Long-term results of a phase II trial. Br J Cancer 81, 1206–1212 (1999). https://doi.org/10.1038/sj.bjc.6690830
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.bjc.6690830
Keywords
This article is cited by
-
Redefining the role of surgery in early small-cell lung cancer
Langenbeck's Archives of Surgery (2022)
-
Behandlung des kleinzelligen Lungenkarzinoms
Der Onkologe (2021)
-
Multimodale Therapie des SCLC in den Stadien I–III
Der Onkologe (2017)
-
RETRACTED ARTICLE: Gene expression profiles on predicting protein interaction network and exploring of new treatments for lung cancer
Molecular Biology Reports (2014)
-
The Role of Radiation Therapy in Small Cell Lung Cancer
Current Oncology Reports (2013)
